Levels of Serum Brain-Derived Neurotrophic Factor in Schizophrenia.


Journal Article

Recent meta-analyses of serum brain-derived neurotrophic factor (BDNF) have reported lower levels in patients with schizophrenia. However, most studies did not consider the potential confounding effects of time of collection, age, sex, smoking, and obesity. Here, we sought to examine differences in serum BDNF between medicated patients with schizophrenia compared with control subjects, taking into consideration the potential confounders of serum BDNF. Serum was obtained from a sample of fasted blood collected from all participants, and BDNF was assayed on a commercially available kit. After adjusting for potential confounders, there was no statistically significant difference between cases and control subjects (p = 0.261). In the model, body mass index emerged as the most significant predictor of serum BDNF (β = 0.22, p = 0.009). The present study did not support a role for serum BDNF as a biomarker in schizophrenia. This could be due to the nonspecific nature of serum BDNF and its association with both mental and physical conditions.

Full Text

Cited Authors

  • Lee, J; Nurjono, M; Lee, T-S

Published Date

  • August 2016

Published In

Volume / Issue

  • 204 / 8

Start / End Page

  • 636 - 639

PubMed ID

  • 27479612

Pubmed Central ID

  • 27479612

Electronic International Standard Serial Number (EISSN)

  • 1539-736X

International Standard Serial Number (ISSN)

  • 0022-3018

Digital Object Identifier (DOI)

  • 10.1097/nmd.0000000000000463


  • eng